BGI Genomics released the State of Colorectal Cancer Awareness Report to explore the biggest challenges and attitudes around awareness and screening. The Colorectal Cancer Screening (CRC) report is the first report to conduct a global survey of the world’s third most common cancer, colorectal cancer. The report was released on World Health Day on 7 April 2023, in line with the goal of achieving “Health For All” and is committed to addressing current and future health challenges.
This report is the first in this area. Aims to better understand the awareness situation about colon cancer. including attitudes and practices in colorectal cancer screening for general risk groups and hereditary risk groups It surveyed 1,817 respondents from 6 countries and regions including the United Kingdom. (Western Europe), Hungary (Eastern Europe), Saudi Arabia (Middle East and Africa), Thailand (South East Asia), and Mainland China and Hong Kong. (North Asia)
Although 51.5% of respondents reported insufficient information about colon cancer and 34.5% said cost reasons prevented them from undergoing colorectal cancer screening. At the same time, the report also revealed several positive findings. For example, 88.8% felt more likely to be screened. Knowing that early detection of colon cancer has a 5-year survival rate of 90%.
“Early detection of colon cancer provides the best outcomes for individuals and health service policies. Sometimes the price of treating late stage colon cancer is more than ten times higher than that of early stage. But the survival rate is much lower,” said Dr. Yantao Li, Director of Colon Cancer Screening for Southeast Asia at BGI Genomics. Because of this, many countries or regions support early screening. For example, the European Commission is now stepping up screening for colon cancer.”
Other key findings from this report include:
A colonoscopy is the most well-known screening test. But there are also aspects that can raise awareness about other types of testing, such as faecal testing. Although colonoscopy (68.2%) is the most well-known screening test, However, it is more expensive and more complicated than stool testing. It is less well-known with 49.5% of the population. There is a need to raise awareness about faecal testing. To promote this option which is more affordable and more flexible.
The physician was the most important factor for respondents in attending asymptomatic screening. 62.5% would listen to a doctor’s recommendation to undergo colon cancer screening. Therefore, it is necessary for physicians to be more aware about the symptoms of colon cancer. Ask the right questions to identify likely hereditary risks. and offering different types of screening options to patients to meet different lifestyles and budgets in our opinion The best colon cancer screening test is the one the patient will take.
Respondents differed when asked about bringing family members in for screening. 55.7% said a family history of colon cancer increased their risk. National Comprehensive Cancer Network (NCCN) guidelines suggest that these family members should begin screening at age 40, or 10 years before their first familial colon cancer diagnosis. 67.2% of people with a history of colon cancer or a family history of colon cancer took a family member for screening. But overall, only 31.2% of respondents had taken a family member for colon cancer screening.
Read and view national or regional comparisons at this link. To access the full BGI Genomics Colorectal Cancer Awareness Report 2023
About BGI Genomics and Colotect
Headquartered in Shenzhen, China, BGI Genomics is a leading global provider of integrated precision medicine solutions. In July 2017, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. As a subsidiary of the BGI Group (BGI Group)
Colotect is a non-invasive DNA test developed by BGI Genomics to detect colorectal cancer and malignant lesions. Colotect uses multiplex methylation-specific PCR (MSP) technology to identify abnormal DNA methylation that is a biomarker for colorectal cancer from colon cancer. stool sample with 88% susceptibility to colon cancer and for early detection The sensitivity of detecting high-risk tumors was 46%, both of which were considered superior to traditional stool tests.
Image – https://mma.prnewswire.com/media/2049211/Is_CRC_information_readily.jpg
Caption – Is there enough information about colon cancer?
Image – https://mma.prnewswire.com/media/2049212/image_5011512_29694509.jpg
Caption – What factors prevent you from being screened?